What Dilopin Treats: Main Uses and Benefits

Dilopin is commonly used to help manage symptoms related to Systemic Arterial Hypertension and Angina Pectoris, including the chronic stable and vaspastic forms. This addresses conditions characterized by systemic imbalance and heightened physiological strain. The medication is considered relevant in contexts marked by increased discomfort or tension.

The medication assists with managing chronic high blood pressure, which may assist with the management of long-term cardiovascular risk, and supports easing the overall burden of chest pain episodes. This dual approach helps patients cope more steadily with symptom fluctuations in daily living.

“This application provides support that helps ease the overall symptom burden associated with vascular strain.”

It is relevant for continuous symptomatic support, particularly in patient groups such as adults and children (over six) requiring control of blood pressure.

---

Quick Fact: Symptomatic Support

Property	Description
Primary Indication	Hypertension
Secondary Indication	Chronic Stable Angina, Vasospastic Angina
Symptom Management	Elevated arterial pressure, Chest pain episodes
Key Patient Benefit	Supports reduction of long-term cardiovascular risk

Regulatory References

1. NIH MedlinePlus Drug Information on Amlodipine

Who can and cannot use Dilopin? (Official Eligibility Information)

Official regulatory documents define the eligible population based on specific contraindications and required caution, primarily concerning pre-existing heart conditions and hypersensitivity. This medicine is generally established for adults who do not have documented reasons for exclusion.

---

Populations for whom use is Contraindicated (Must Not Use):

Classification	Condition/Exclusion
Hypersensitivity	Known allergy to the medicine or its components.
Severe Conduction Defects	Sick sinus syndrome or second-/third-degree Atrioventricular (AV) block, unless a functioning ventricular pacemaker is present.
Accessory Pathway	Atrial fibrillation or flutter associated with an accessory bypass tract (e.g., Wolff-Parkinson-White syndrome).
Acute Unstable Cardiac State	Acute myocardial infarction complicated by pulmonary congestion.
Severe Hypotension	Systolic blood pressure below 90 mm Hg.

---

Use Requires Caution or Monitoring (Restricted Use):

Classification	Condition/Consideration
Organ Impairment	Patients with impaired renal or hepatic function.
Ventricular Function	Patients with impaired left ventricular function or congestive heart failure.

The presence of a functioning ventricular pacemaker explicitly modifies the contraindication for sick sinus syndrome and AV block, allowing for use in these specific circumstances. Use in pediatric populations is typically not established or is limited in official regulatory documentation.

Interactions with other medicines and products

Dilopin (amlodipine) may interact with several medicinal products, potentially requiring dose adjustment or increased clinical monitoring as specified in official regulatory documentation.

Documented Interacting Categories

Category	Relevant Constraint	Implication Basis
CYP3A4 Inhibitors (e.g., diltiazem, ketoconazole)	Close monitoring is necessary.	Increased systemic exposure of Dilopin.
CYP3A4 Inducers (e.g., rifampicin)	Monitoring for effectiveness is required.	Variable plasma concentrations of Dilopin.
Simvastatin (High Doses)	Maximum dose restriction to 20 mg daily.	Dilopin inhibits Simvastatin's metabolism, increasing exposure.
Other Antihypertensives	Increased blood pressure monitoring required.	Potential for additive blood pressure lowering effects.

Clinical Management Requirements

Official labeling mandates that the dose of Simvastatin must not exceed 20 mg per day when co-administered due to Dilopin’s inhibitory effect on the drug-metabolizing enzyme CYP3A4. Concomitant use with strong CYP3A4 inhibitors may lead to a significant increase in Dilopin exposure, necessitating caution and monitoring for excessive blood pressure reduction. Conversely, co-administration with CYP3A4 inducers may decrease Dilopin's plasma levels, requiring blood pressure checks to ensure therapeutic efficacy. These restrictions and monitoring requirements define the product's official interaction profile.

How Dilopin Works

Dilopin (Amlodipine) operates as a calcium ion influx inhibitor, engaging a mechanism characterized by molecular blockade that modulates the circulatory system. The core action is initiated by binding to the voltage-dependent L-type calcium channels (CaV 1.2) found on the membrane of vascular smooth muscle cells in peripheral arteries.

This specific interaction prevents the necessary transmembrane flow of extracellular calcium ions into the cell cytoplasm. The resulting reduction in intracellular calcium concentration inhibits the activation of the cellular contractile apparatus, thereby inducing arterial smooth muscle relaxation (vasodilation) throughout the periphery.

This physiological cascade directly reduces the total opposition to blood flow, a parameter known as the Systemic Vascular Resistance or afterload. The consequence of this systemic modulation is a reduction in the mechanical workload exerted on the heart muscle, resulting in a sustained adjustment of circulatory dynamics.

Official Dosing and Administration Principles

Dilopin (Amlodipine) is approved for oral administration only, typically as a tablet or oral solution. Its use is characterized by a simple, once-daily schedule intended for long-term management.

Dosing and Frequency

Indication	Adult Starting Dose	Adult Maximum Dose
Hypertension & Angina	5 mg once daily	10 mg once daily

The standard adult starting dose is 5 mg taken once daily. The dose can be adjusted up to the maximum limit of 10 mg once daily. To assess the body's full response, dosage increases should generally proceed over a period of 7 to 14 days. This structured, gradual adjustment is required to ensure steady levels of the medication are reached.

Administration Conditions and Timing

Dilopin is taken once daily and can be administered with or without food. To ensure consistent drug levels, it is important to take the medication at approximately the same time each day.

If a dose is missed, it is recommended to take it as soon as it is remembered, unless it is less than 12 hours before the next scheduled dose. In that case, the missed dose should be skipped entirely, and the regular schedule resumed. Never take a double dose to make up for a missed one.

Population-Specific Use

For patients who are small, fragile, or those with hepatic insufficiency, the official starting dose may be reduced to 2.5 mg once daily. For children aged 6 to 17 years being treated for hypertension, the effective daily dose ranges from 2.5 mg to 5 mg, and doses above 5 mg have not been studied in this population.

Research Evidence / Overview of Studies for Dilopin

---

Evidence for use in Systemic Arterial Hypertension (High Blood Pressure)

The research on Dilopin (Amlodipine) for high blood pressure is rooted in large-scale, long-term randomized controlled trials (RCTs). These studies explored how blood pressure measurements change over time, comparing Dilopin against inactive placebos and against several other types of blood pressure medications. Primary outcomes monitored included outcomes related to systemic imbalance, such as measured shifts in systolic and diastolic blood pressure (BP), and outcomes related to the occurrence of major cardiovascular conditions. Findings describe patterns observed in the studies related to BP changes and suggested potential long-term patterns related to the occurrence of major events, such as stroke or heart attack, when compared to certain other regimens evaluated in the trials.

Evidence for use in Angina Pectoris (Chest Pain)

Dilopin was evaluated in randomized, controlled studies focusing on fluctuating symptoms, such as chest pain, in adults diagnosed with chronic stable or vasospastic angina. Research monitored outcomes reflecting daily functioning, tracking participants' ability to perform symptom-limited exercise and the frequency of angina episodes. Findings describe patterns observed in the studies related to changes in measured exercise capacity and reported shifts in the average number of weekly angina attacks and in the amount of acute nitrate medication consumed.

Research Gaps and Areas of Uncertainty

The body of evidence, while extensive, is associated with certain research limitations. One key limitation is that long-term effects are not fully established or well-characterized for specific outcomes in pediatric patients (under 18 years of age). In the largest long-term trials, Dilopin was often studied within complex combination therapy strategies, meaning comparative evidence for Dilopin as a monotherapy (single drug) against all available modern treatments is sometimes lacking. Additionally, data exploring the progression of atherosclerosis (hardening of the arteries) has shown inconsistent results across studies, depending on the specific measurement method used.

Common questions about Dilopin (FAQ)

Q: How quickly does Dilopin typically start to have an effect?

According to official product information, the majority of the blood pressure-lowering effect is typically attained within two weeks after starting therapy or making an adjustment to the dose. This time frame is needed to allow the medicine to reach steady levels in the body.

Q: Can people who are older safely use Dilopin?

Regulatory documents specify that the initial dose for older adults, or those who are small or fragile, may be reduced compared to the standard adult starting amount. This is due to observations that the medicine's clearance, or how it is removed from the body, may be slowed in this population.

Q: Are there any food items that I should be careful about when using Dilopin?

Official product information indicates that the use of grapefruit or grapefruit juice is described in official documents as generally avoided when taking this medication. This is because grapefruit may increase the amount of medicine absorbed by the body, potentially enhancing its blood pressure-lowering effects.

Q: Is it normal to feel tired during the first week of using Dilopin?

Official safety documents list side effects like fatigue (tiredness) and somnolence (drowsiness) as common adverse reactions. These specific effects are noted in the product information as being more common at the beginning of treatment.

Q: Can Dilopin affect my ability to drive or operate machinery?

According to regulatory information, this medicine can have a minor or moderate influence on the ability to drive or use machines. If you experience side effects such as headache, dizziness, or fatigue, regulatory information advises caution, particularly when starting the medicine, if such side effects occur.

Q: How is the safety of Dilopin monitored after it is approved?

The safety of this medicine is continually monitored through a regulatory process called post-marketing surveillance. This is achieved through the official reporting of all suspected adverse reactions, which is a required process to ensure the ongoing evaluation of the medicine’s safety profile.

Q: Does Dilopin require special blood tests while I am taking it?

Official interaction documents mention that when taking this medicine alongside certain other medications (such as cyclosporine or tacrolimus), monitoring of blood levels may be required. This is done to help manage the exposure and effects of the co-administered drug.

Q: Is it possible for Dilopin to interact with herbal supplements?

The official interaction profile specifically lists certain strong CYP3A4-inducing substances. This category includes the herbal supplement Hypericum perforatum (St. John’s Wort), which may decrease the amount of the medicine in the blood. Co-administration with such inducers may require blood pressure checks to ensure therapeutic efficacy, as noted in the interaction profile.

Q: How long does Dilopin stay in the body after the last use?

Official pharmacological data indicates that this medicine has a long duration of action in the body. Its terminal elimination half-life, which is the time it takes for half of the medicine to be removed, is officially described as being between 30 and 50 hours.

Q: Is Dilopin safe for women who might become pregnant?

Official regulatory notes indicate that there is inadequate human data available on the use of this medication during pregnancy to fully inform a drug-related risk. Therefore, use during pregnancy is described in official documents as being permissible only if the potential benefit to the patient is judged to outweigh the potential risk to the fetus.

Q: Does research show that Dilopin helps everyone who takes it?

Research evidence frames the efficacy of the medicine in terms of the likelihood of achieving specific clinical goals, such as reaching a target blood pressure. The magnitude of the response is also described as being correlated with the height of the patient's blood pressure prior to treatment.

Q: Does Dilopin have any known interactions with alcohol?

Regulatory information notes that drinking alcohol may lead to an increased blood pressure-lowering effect from the medicine. This additive effect can potentially result in symptoms such as headache, dizziness, or sleepiness.

Q: Is Dilopin safe for people with kidney problems?

Official pharmacokinetic studies indicate that the way the medicine works in the body is not significantly influenced by kidney impairment. As a result, patients with kidney problems may receive the usual initial dose as described in the official product information.

Q: Why is Dilopin sometimes referred to by a different name?

The medicine is generally referred to by its brand name, Dilopin, and its official active ingredient name, Amlodipine. Using both a brand name and the active ingredient name is consistent with the standard naming conventions for medicinal products across various regulatory bodies.

Storage and Disposal of Dilopin (Amlodipine Besylate Tablets)

Dilopin must be stored at Controlled Room Temperature, specifically between 20 C to 25 C (68 F to 77 F), with temporary excursions permitted up to 30 C. The medicine must be protected from light and moisture and kept in its original container, tightly closed, to maintain stability.

---

Official Requirements

Condition	Requirement
Child Safety	Keep this and all medicines out of the reach of children.
Disposal	Discard via a drug take-back program or by following FDA household guidelines; do not flush.

These conditions are mandatory and defined by regulatory documentation to ensure the quality and safety of the product.